Related Experiment Videos
Non-transferrin-bound iron induced by myeloablative chemotherapy
S J Bradley1, I Gosriwitana, S Srichairatanakool
1Department of Haematology, University College London.
British Journal of Haematology
|December 31, 1997
Summary
Non-transferrin-bound iron (NTBI) appears in most patients during chemotherapy, peaking at 5 days. Its formation is linked to reduced red blood cell production, not the chemotherapy drug itself.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Background:
- Non-transferrin-bound iron (NTBI) in plasma is linked to organ damage and infection risk in chemotherapy patients.
- The origin of NTBI during myelosuppressive chemotherapy remains unclear.
Purpose of the Study:
- To investigate the appearance and disappearance kinetics of NTBI during chemotherapy.
- To identify the source of NTBI in patients receiving myelosuppressive chemotherapy.
Main Methods:
- Quantified NTBI levels in 24 patients before, during, and after chemotherapy.
- Assessed transferrin saturation, serum iron, ferritin, reticulocyte count, and serum transferrin receptor (TfR) levels.
- Investigated the effect of daunorubicin on NTBI formation in vitro.
Main Results:
- NTBI was detected in 19 of 24 patients post-chemotherapy, with peak levels at 5 days.
- NTBI appearance correlated with increased transferrin saturation but also occurred independently.
- Daunorubicin did not directly cause NTBI release from serum.
- NTBI levels showed no correlation with iron/ferritin, transfusions, disease stage, or chemotherapy type.
- NTBI emergence was inversely related to falling reticulocyte and TfR levels.
Conclusions:
- Chemotherapy induces NTBI formation, primarily due to the suppression of erythropoietic activity.
- NTBI is not directly caused by the chemotherapy agent daunorubicin.
- Understanding NTBI kinetics is crucial for managing chemotherapy-related complications.